Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 29 54 43 15 71


External Ids:

Disease Ontology 12 DOID:0050459
MeSH 43 D054559
NCIt 49 C113750
SNOMED-CT 67 20165001
UMLS 71 C0085681

Summaries for Hyperphosphatemia

Disease Ontology : 12 A phosphorus metabolism disease characterized by hyperphosphatemia and abnormal deposits of phosphate and calcium in joints and soft tissues, results from abnomral phosphorus metabolism and has material basis in mutations in the FGF23, GALNT3 or KL gene.

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial, 1 and familial tumoral calcinosis. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Mesenchymal Stem Cells and Lineage-specific Markers and Endochondral Ossification. The drugs Alendronate and Calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and smooth muscle, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial, 1 34.2 PTH PHEX KL GALNT3 FGF23
2 familial tumoral calcinosis 32.9 PHEX KL GALNT3 FGF23
3 hypoparathyroidism, familial isolated, 1 32.7 PTH GCM2
4 pseudohypoparathyroidism 32.6 STX16 PTH GNAS BGLAP
5 pseudohypoparathyroidism, type ib 32.6 STX16 PTH GNAS BGLAP
6 pseudohypoparathyroidism, type ia 32.4 STX16 PTH GNAS
7 hypoparathyroidism 31.8 VDR PTH GNAS GCM2 FGF23 CASR
8 end stage renal disease 31.4 PTH FGF23 CRP ALB
9 hypocalcemia, autosomal dominant 1 31.2 VDR PTH GNAS GCM2 FGF23 CASR
10 metabolic acidosis 30.9 PTH FGF23 BGLAP ALB
11 deficiency anemia 30.6 PTH FGF23 CRP ALB
12 hyperuricemia 30.5 PTH CRP ALB
13 hypervitaminosis d 30.1 VDR PTH KL GALNT3 FGF23
14 calcinosis 30.0 SPP1 PHEX MGP KL GNAS GALNT3
15 oncogenic osteomalacia 30.0 SFRP4 PTH PHEX FGF23
16 fanconi syndrome 30.0 SLC34A1 PTH PHEX FGF23 ALB
17 hypophosphatemic rickets, x-linked recessive 30.0 VDR SLC34A1 SFRP4 PHEX FGF23
18 hyperostosis 29.9 TNFRSF11B SPP1 KL GALNT3 FGF23
19 osteitis fibrosa 29.9 PTH GNAS FGF23 CASR BGLAP
20 hyperthyroidism 29.8 PTH GNAS CRP BGLAP ALB
21 renal osteodystrophy 29.8 VDR TNFRSF11B PTH FGF23 CASR BGLAP
22 hypophosphatasia 29.6 SPP1 RUNX2 PTH PHEX FGF23 BGLAP
23 secondary hyperparathyroidism 29.4 VDR TNFRSF11B PTH PHEX KL FGF23
24 hypophosphatemic rickets, autosomal dominant 29.4 SFRP4 PTH PHEX KL GALNT3 FGF23
25 hyperparathyroidism 29.3 VDR TNFRSF11B PTH PHEX KL GCM2
26 osteomalacia 29.2 VDR SLC34A1 SFRP4 PTH PHEX FGF23
27 calciphylaxis 29.2 VDR SPP1 PTH MGP FGF23 CASR
28 hypophosphatemic rickets, x-linked dominant 29.1 SPP1 SLC34A1 SFRP4 PTH PHEX KL
29 hypophosphatemia 29.0 VDR SPP1 SLC34A1 SFRP4 PTH PHEX
30 nephrocalcinosis 29.0 SPP1 SLC34A1 PTH PHEX FGF23 CASR
31 myeloma, multiple 28.9 TNFRSF11B SPP1 RUNX2 PTH CRP BGLAP
32 bone disease 28.8 VDR TNFRSF11B SPP1 RUNX2 PTH PHEX
33 fibrous dysplasia 28.7 TNFRSF11B SPP1 RUNX2 GNAS FGF23 BGLAP
34 kidney disease 28.7 VDR TNFRSF11B SPP1 PTH MGP FGF23
35 vascular disease 28.5 TNFRSF11B SPP1 PTH MGP CRP ALB
36 uremia 28.4 VDR TNFRSF11B SPP1 PTH MGP CRP
37 rickets 28.2 VDR SPP1 SLC34A1 SFRP4 PTH PHEX
38 primary hyperparathyroidism 28.2 VDR TNFRSF11B PTH KL GCM2 FGF23
39 chronic kidney disease 28.0 VDR TNFRSF11B SPP1 RUNX2 PTH MGP
40 diabetes mellitus 27.6 VDR TNFRSF11B SPP1 PTH FGF23 CRP
41 bone resorption disease 27.4 VDR TNFRSF11B SPP1 RUNX2 PTH FGF23
42 osteoporosis 26.3 VDR TNFRSF11B SPP1 SLC34A1 RUNX2 PTH
43 hyperphosphatemia, polyuria, and seizures 12.4
44 tumoral calcinosis, hyperphosphatemic, familial, 2 11.7
45 tumoral calcinosis, hyperphosphatemic, familial, 3 11.7
46 pseudohypoparathyroidism, type ii 11.1
47 hypoparathyroidism-retardation-dysmorphism syndrome 11.1
48 hypoparathyroidism, x-linked 11.1
49 pseudohypoparathyroidism, type ic 11.1
50 hypoparathyroidism, familial isolated, 2 11.1

Graphical network of the top 20 diseases related to Hyperphosphatemia:

Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 ALB CRP FGF23 GALNT3 GNAS KL
2 cellular MP:0005384 10.43 ALB BGLAP CASR GALNT3 GCM2 GNAS
3 growth/size/body region MP:0005378 10.41 CASR FGF23 GALNT3 GNAS KL MGP
4 homeostasis/metabolism MP:0005376 10.41 ALB BGLAP CASR CRP FGF23 GALNT3
5 immune system MP:0005387 10.36 ALB BGLAP CASR CRP FGF23 GALNT3
6 hematopoietic system MP:0005397 10.34 BGLAP CASR FGF23 GALNT3 GNAS KL
7 endocrine/exocrine gland MP:0005379 10.3 ALB BGLAP CASR FGF23 GALNT3 GCM2
8 craniofacial MP:0005382 10.25 GALNT3 GCM2 GNAS KL PHEX PTH
9 mortality/aging MP:0010768 10.22 ALB CASR FGF23 GCM2 GNAS KL
10 digestive/alimentary MP:0005381 10.19 ALB CASR FGF23 GALNT3 KL PHEX
11 limbs/digits/tail MP:0005371 10.1 FGF23 GALNT3 GNAS KL PHEX PTH
12 integument MP:0010771 10.09 CASR FGF23 GALNT3 GNAS KL RUNX2
13 renal/urinary system MP:0005367 9.97 ALB CASR FGF23 GALNT3 GCM2 GNAS
14 muscle MP:0005369 9.96 ALB CASR GALNT3 GNAS KL MGP
15 liver/biliary system MP:0005370 9.91 ALB GNAS KL PHEX RUNX2 SLC20A1
16 reproductive system MP:0005389 9.61 BGLAP FGF23 GALNT3 KL RUNX2 SFRP4
17 skeleton MP:0005390 9.58 BGLAP CASR FGF23 GALNT3 GCM2 GNAS

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
Calcium carbonate Approved, Investigational Phase 4 471-34-1
Atorvastatin Approved Phase 4 134523-00-5 60823
Sodium citrate Approved, Investigational Phase 4 68-04-2
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
10 Antacids Phase 4
11 Anti-Ulcer Agents Phase 4
12 Gastrointestinal Agents Phase 4
13 Anticoagulants Phase 4
14 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
15 Liver Extracts Phase 4
16 Anticholesteremic Agents Phase 4
17 Laxatives Phase 4
18 Cathartics Phase 4
19 Picosulfate sodium Phase 4
20 Cola Phase 4
21 Calcium Supplement Phase 4
22 Citrate Phase 4
23 Protective Agents Phase 4
24 Antioxidants Phase 4
25 Hematinics Phase 4
26 Ferric Compounds Phase 4
27 Vasoconstrictor Agents Phase 4
carbamide peroxide Approved Phase 3 124-43-6
Sevelamer Approved Phase 3 52757-95-6
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
Cinacalcet Approved Phase 3 226256-56-0 156419
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
35 Chelating Agents Phase 3
36 Vitamin B Complex Phase 3
37 Vitamin B3 Phase 3
38 Nicotinic Acids Phase 3
39 Folate Phase 3
40 Vasodilator Agents Phase 3
41 Lipid Regulating Agents Phase 3
42 Hypolipidemic Agents Phase 3
43 Vitamin B9 Phase 3
44 Antimetabolites Phase 3
45 Pharmaceutical Solutions Phase 3
46 Hormone Antagonists Phase 3
47 Bile Acids and Salts Phase 3
Angiotensin II Approved, Investigational Phase 2 4474-91-3, 11128-99-7, 68521-88-0 172198
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 186)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
3 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
4 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
5 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
6 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
7 A Phase IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenol Compared to Existing Therapy in Adults With End Stage Renal Disease Treated for Hyperphosphatemia Completed NCT00160121 Phase 4 Lanthanum carbonate
8 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
9 Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
10 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
11 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
12 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
14 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study From Kaiser Permanente Southern California Active, not recruiting NCT03079869 Phase 4 Ferric Citrate
15 A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE) Active, not recruiting NCT03988920 Phase 4 Tenapanor;Sevelamer Carbonate
16 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Active, not recruiting NCT02999204 Phase 4 Vitamin D3
17 Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease Active, not recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
18 Effect of Auryxia on ESA Utilization in ESRD Patients With High Ferritin & Low Transferrin Saturation: A Pilot Project Active, not recruiting NCT03055598 Phase 4 Ferric Citrate
19 Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
20 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Not yet recruiting NCT04046263 Phase 4 Sucroferric Oxyhydroxide Chewable Tablet
21 A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
22 A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
23 Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis Unknown status NCT03202407 Phase 3 Calcium acetate and sevelamer hydrochloride
24 Changes in Biochemical and Vascular Parameters w/Lanthanum Carbonate & Calcium Acetate Therapy Compared to Dietary Intervention in Pts w/Stage 3 & 4 Chronic Kidney Disease & Abnormal Phosphorus Homeostasis: a Randomized Controlled Trial Unknown status NCT01357317 Phase 3 Phosphorus binder
25 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
26 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
27 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
28 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
29 Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
30 Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
31 A Phase 3 Study in Patients With Chronic Kidney Disease (CKD) With Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
32 A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
33 A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
34 ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
35 ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
36 A Double-blind, Randomized, Placebo-controlled Multi-center Trial to Compare the Phosphate Lowering Efficacy of Different Doses of SBR759 to Placebo Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
37 Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
38 A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
39 An Open-label, Long-term Extension Study of Lanthanum Carbonate 750 to 2,250 mg in Hyperphosphatemia in Patients With Chronic Kidney Disease Not on Dialysis (52 Weeks Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
40 A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
41 A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups) Completed NCT00542386 Phase 3 MCI-196;Placebo
42 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
43 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
44 A 26-Wk, Phase 3, Open Label Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period Followed by an Open Label Long Term Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Completed NCT03427125 Phase 3 Tenapanor;Placebo;Sevelamer Carbonate
45 An 8-week, Multicenter, Randomized, Double-Blind, Parallel Group Study With a 4-week, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Efficacy, Safety, and Tolerability of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
46 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects With Hyperphosphatemia Completed NCT03824587 Phase 2, Phase 3 Tenapanor;Placebo
47 A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo Completed NCT03001011 Phase 3 Placebo;Sevelamer Carbonate (GZ419831)
48 A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
49 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period Completed NCT01074125 Phase 3 ferric citrate
50 EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease Completed NCT00211978 Phase 3 calcium acetate;placebo

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 29

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

Kidney, Bone, Smooth Muscle, Colon, Heart, Liver, Endothelial

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 3281)
# Title Authors PMID Year
The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. 61 54
20180772 2010
Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib. 61 54
20427744 2010
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. 54 61
20358599 2010
Recent advances in renal phosphate handling. 54 61
20177401 2010
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? 54 61
19965540 2010
Mapping of human autoantibody binding sites on the calcium-sensing receptor. 54 61
19580466 2010
In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. 61 54
20031638 2009
The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. 61 54
19808223 2009
Emerging topics in pediatric bone and mineral disorders 2008. 54 61
19615558 2009
[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD]. 61 54
19329835 2009
[Disturbance of phosphorus metabolism in chronic kidney disease]. 54 61
19182354 2009
Vascular calcification in chronic kidney disease: pathogenesis and clinical implications. 61 54
19121777 2009
Impact of disturbances of calcium and phosphate metabolism on vascular calcification and clinical outcomes in patients with chronic kidney disease. 61 54
19295198 2009
An adolescent boy with thalassemia major presenting with bone pain, numbness, tetanic contractions and growth and pubertal delay: panhypopituitarism and combined vitamin D and parathyroid defects. 61 54
19337171 2008
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. 61 54
18687639 2008
The mechanism of phosphorus as a cardiovascular risk factor in CKD. 54 61
18417722 2008
Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. 54 61
18166826 2008
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. 61 54
17914251 2008
Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. 54 61
17943081 2008
Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. 61 54
18290715 2007
Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. 54 61
17976083 2007
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. 61 54
17710231 2007
Advantage of a low glycemic index and low phosphate diet on diabetic nephropathy and aging-related diseases. 61 54
17878688 2007
Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. 54 61
17565275 2007
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. 61 54
17635819 2007
Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. 54 61
17464094 2007
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. 61 54
17311862 2007
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. 61 54
17129170 2007
Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach. 61 54
17178702 2006
Regulation of parathyroid function in chronic kidney disease (CKD). 54 61
17009074 2006
Osteopontin expression in vascular smooth muscle cells in patients with end-stage renal disease. 61 54
16817793 2006
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]. 54 61
16733465 2006
Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. 54 61
16395276 2006
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. 54 61
16691036 2006
[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease]. 54 61
16272627 2005
[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism]. 61 54
16272628 2005
Fibroblast growth factor 23 and its receptors. 61 54
16076372 2005
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. 54 61
15827108 2005
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. 54 61
15917335 2005
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. 54 61
15590700 2005
Hyperphosphatemia in renal failure. 54 61
15627730 2005
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. 61 54
15579309 2004
Management of calcium and bone abnormalities in hemodialysis patients. 61 54
15490408 2004
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. 54 61
15332221 2004
FGF-23 is elevated by chronic hyperphosphatemia. 54 61
15356053 2004
What have we learnt about the regulation of phosphate metabolism? 61 54
15199289 2004
FGF-23 in patients with end-stage renal disease on hemodialysis. 61 54
15086938 2004
Vitamin D receptor and analogs. 61 54
14730505 2004
[The present state of vitamin D supplementation or treatment among chronic dialysis patients]. 54 61
15576951 2004
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. 54 61
14633152 2003

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.63 STX16 SPP1 SLC34A1 PHEX GNAS GALNT3
2 extracellular space GO:0005615 9.61 TNFRSF11B SPP1 SFRP4 PTH KL FGF23
3 extracellular region GO:0005576 9.36 TNFRSF11B SPP1 SFRP4 PTH MGP KL

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 VDR SFRP4 RUNX2 CRP CASR
2 response to drug GO:0042493 9.95 TNFRSF11B SLC34A1 PTH GNAS BGLAP
3 cellular protein metabolic process GO:0044267 9.88 SPP1 SLC34A1 FGF23 ALB
4 cellular calcium ion homeostasis GO:0006874 9.81 VDR PTH GCM2 CASR
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.77 KL GALNT3 FGF23
6 bone development GO:0060348 9.74 PHEX GNAS BGLAP
7 biomineral tissue development GO:0031214 9.71 SPP1 SLC20A1 PHEX BGLAP
8 regulation of bone mineralization GO:0030500 9.67 MGP FGF23 BGLAP
9 response to magnesium ion GO:0032026 9.65 TNFRSF11B SLC34A1 FGF23
10 cellular response to parathyroid hormone stimulus GO:0071374 9.63 SLC34A1 PHEX FGF23
11 ossification GO:0001503 9.63 SPP1 SLC34A1 RUNX2 MGP CASR BGLAP
12 response to growth hormone GO:0060416 9.62 SLC34A1 PHEX
13 energy reserve metabolic process GO:0006112 9.62 KL GNAS
14 response to vitamin D GO:0033280 9.62 SPP1 PTH PHEX BGLAP
15 vitamin D metabolic process GO:0042359 9.61 VDR FGF23
16 phosphate ion transport GO:0006817 9.61 SLC34A1 SLC20A1
17 cellular phosphate ion homeostasis GO:0030643 9.61 SLC34A1 GCM2 FGF23
18 response to fibroblast growth factor GO:0071774 9.58 PTH CASR
19 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.56 KL FGF23
20 cellular response to vitamin D GO:0071305 9.56 PHEX FGF23 CASR BGLAP
21 response to sodium phosphate GO:1904383 9.54 PHEX FGF23
22 response to parathyroid hormone GO:0071107 9.54 SLC34A1 PTH GNAS
23 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.52 VDR FGF23
24 skeletal system development GO:0001501 9.5 VDR TNFRSF11B RUNX2 PTH PHEX GNAS
25 phosphate ion homeostasis GO:0055062 8.92 SLC34A1 SFRP4 PTH FGF23

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.56 VDR TNFRSF11B SLC20A1 CASR
2 sodium:phosphate symporter activity GO:0005436 9.16 SLC34A1 SLC20A1
3 vitamin D binding GO:0005499 8.96 VDR KL
4 structural constituent of bone GO:0008147 8.62 MGP BGLAP

Sources for Hyperphosphatemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....